Blood DNA test may predict return of rare blood cancer
NCT ID NCT04893564
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is looking at whether pieces of tumor DNA found in the blood (called circulating tumor DNA) can help predict if Waldenström macroglobulinemia will come back after treatment. Researchers will collect blood and bone marrow samples from 90 patients after their first 6 months of therapy and follow them for up to 3 years. The goal is to see if the presence of this DNA is linked to a higher risk of relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients are at higher risk of their cancer returning, allowing for earlier intervention.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to any change in patient care, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens
RECRUITINGAmiens, 80480, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Smartwatches track hidden heart risk in blood cancer patients
- Can a tailored exercise and diet plan beat cancer fatigue?
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug duo shows promise for rare blood cancer